Fmr LLC Sells 85,667 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Fmr LLC decreased its position in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 4.7% in the 3rd quarter, Holdings Channel reports. The fund owned 1,743,498 shares of the company’s stock after selling 85,667 shares during the quarter. Fmr LLC’s holdings in Entrada Therapeutics were worth $27,861,000 as of its most recent filing with the SEC.

Several other large investors also recently added to or reduced their stakes in the company. US Bancorp DE purchased a new stake in Entrada Therapeutics during the third quarter valued at about $42,000. SG Americas Securities LLC bought a new stake in shares of Entrada Therapeutics in the third quarter valued at approximately $156,000. Acadian Asset Management LLC lifted its stake in shares of Entrada Therapeutics by 135.1% during the 2nd quarter. Acadian Asset Management LLC now owns 13,367 shares of the company’s stock valued at $190,000 after buying an additional 7,682 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Entrada Therapeutics by 87.2% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 27,631 shares of the company’s stock worth $394,000 after buying an additional 12,868 shares during the period. Finally, BayBridge Capital Group LLC purchased a new position in Entrada Therapeutics in the 3rd quarter valued at approximately $464,000. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on TRDA shares. Roth Capital upgraded Entrada Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Oppenheimer increased their price objective on Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a report on Wednesday, November 6th. Roth Mkm began coverage on Entrada Therapeutics in a report on Thursday, December 5th. They set a “buy” rating and a $29.00 target price for the company. Finally, HC Wainwright increased their price target on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th.

Insider Activity

In related news, CFO Kory James Wentworth sold 8,637 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $19.98, for a total value of $172,567.26. Following the completion of the transaction, the chief financial officer now directly owns 73,849 shares in the company, valued at approximately $1,475,503.02. The trade was a 10.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Natarajan Sethuraman sold 2,700 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $20.04, for a total value of $54,108.00. Following the sale, the insider now owns 160,888 shares in the company, valued at $3,224,195.52. The trade was a 1.65 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 20,193 shares of company stock worth $399,191. 7.59% of the stock is currently owned by insiders.

Entrada Therapeutics Stock Down 0.3 %

Entrada Therapeutics stock opened at $21.52 on Tuesday. The stock has a market cap of $805.28 million, a price-to-earnings ratio of 13.53 and a beta of -0.18. The business has a 50-day simple moving average of $18.20 and a 200 day simple moving average of $16.53. Entrada Therapeutics, Inc. has a 52 week low of $11.35 and a 52 week high of $21.79.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.